ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Rating of “Buy” by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned an average rating of “Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $77.71.

ANIP has been the topic of several research reports. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th.

ANI Pharmaceuticals Stock Up 2.5 %

ANI Pharmaceuticals stock opened at $55.50 on Friday. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -100.91 and a beta of 0.73. The firm’s fifty day moving average price is $57.57 and its two-hundred day moving average price is $59.70. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.05 earnings per share. On average, equities research analysts predict that ANI Pharmaceuticals will post 3.87 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,231 shares of company stock worth $2,434,286 in the last three months. 12.70% of the stock is owned by insiders.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Innealta Capital LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $65,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the last quarter. XTX Topco Ltd purchased a new stake in ANI Pharmaceuticals during the 2nd quarter valued at about $207,000. HighTower Advisors LLC bought a new stake in ANI Pharmaceuticals during the 3rd quarter valued at about $222,000. Finally, Profund Advisors LLC purchased a new position in ANI Pharmaceuticals in the second quarter worth about $225,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.